MacroGenics Inc (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jon Marc Wigginton also recently made the following trade(s):

  • On Tuesday, November 21st, Jon Marc Wigginton sold 5,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00.
  • On Wednesday, October 25th, Jon Marc Wigginton sold 10,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00.

Shares of MacroGenics Inc (NASDAQ:MGNX) opened at $19.19 on Friday. The firm has a market cap of $717.85, a price-to-earnings ratio of -4.27 and a beta of 2.73. MacroGenics Inc has a 52 week low of $14.36 and a 52 week high of $22.31.

MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm had revenue of $1.70 million during the quarter, compared to analyst estimates of $5.50 million. During the same quarter last year, the business posted ($0.97) EPS. The firm’s revenue was down 48.5% on a year-over-year basis. research analysts expect that MacroGenics Inc will post -0.7 earnings per share for the current year.

MGNX has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Raymond James Financial restated a “buy” rating on shares of MacroGenics in a report on Monday, December 11th. Finally, Citigroup upped their target price on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $30.10.

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of MacroGenics in the 2nd quarter worth $133,000. Legal & General Group Plc increased its holdings in shares of MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 328 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of MacroGenics by 92.2% in the 2nd quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 5,187 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new position in shares of MacroGenics in the 2nd quarter valued at about $203,000. Finally, Virtu KCG Holdings LLC purchased a new position in shares of MacroGenics in the 2nd quarter valued at about $232,000. Institutional investors own 85.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2018/01/20/macrogenics-inc-mgnx-svp-sells-100000-00-in-stock.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.